High risk human papillomavirus
Pro Research Analysisby 
Searched over 200M research papers
High-Risk Human Papillomavirus: Key Genotypes and Cancer Risk
High-risk human papillomavirus (HR-HPV) includes several subtypes, most notably HPV16 and HPV18, that are strongly linked to the development of cancers such as cervical cancer, head and neck squamous cell carcinomas, and, to a lesser extent, lung cancer and anogenital cancers 138. In large population studies, the most common HR-HPV genotypes detected are HPV-52, HPV-16, HPV-53, HPV-58, HPV-51, and HPV-68, with prevalence rates varying by region and age group .
Mechanisms of Oncogenesis: E6 and E7 Oncogenes
The cancer-causing potential of HR-HPV is primarily due to the viral oncogenes E6 and E7. These proteins disrupt normal cell cycle control by targeting key cellular pathways, such as p53 and pRb, leading to uncontrolled cell proliferation and cancerous transformation 110. The balance of E6 and E7 expression is regulated by alternative splicing, and disruptions in this balance can trigger cell death or promote cancer progression . E6 and E7 also affect other cellular processes, including epigenetic regulation and mRNA splicing, further contributing to oncogenesis .
HR-HPV Infection in Immunocompromised Populations
Individuals with compromised immune systems, such as those living with HIV or with primary immunodeficiencies, are at higher risk for persistent HR-HPV infection and related cancers 59. In these populations, HR-HPV can cause persistent, treatment-resistant disease, and the risk of progression to malignancy is significantly increased 59. The mechanisms of HR-HPV-driven cancer in immunocompromised hosts are not fully understood, but immune evasion and viral persistence play major roles .
Co-Infections and Increased Risk
Co-infection with other sexually transmitted infections, such as herpes simplex virus type 2 (HSV-2), has been shown to increase the risk of HR-HPV infection, particularly for HPV-18 and HPV-58 . This highlights the importance of comprehensive sexual health strategies, including prevention of HSV-2 and early HPV vaccination, to reduce the burden of HR-HPV-related diseases .
Screening, Detection, and Biomarkers
HR-HPV testing is a highly effective method for cervical cancer screening, outperforming traditional cytology and visual inspection methods in detecting high-grade cervical lesions . New diagnostic kits, such as the Sansure® Human Papillomavirus DNA Diagnostic Kit, have demonstrated excellent reproducibility for detecting HR-HPV genotypes . Additionally, noninvasive biomarkers like salivary HR-HPV DNA are emerging as valuable tools for detecting and monitoring HPV-driven head and neck cancers, offering favorable prognostic information .
HR-HPV Beyond the Cervix: Head, Neck, and Lung Cancers
While HR-HPV is best known for its role in cervical cancer, it is also implicated in a subset of head and neck cancers, particularly oropharyngeal cancers, and possibly in some lung cancers 78. The presence of HR-HPV DNA in saliva is a promising biomarker for HPV-driven head and neck cancers, and HR-HPV may act as an independent or cooperative carcinogen in lung cancer, though its role in lung cancer remains controversial and requires further research 78.
Conclusion
High-risk human papillomavirus is a major cause of several cancers, with its oncogenic potential driven by the E6 and E7 proteins. The prevalence and impact of HR-HPV vary by genotype, region, and host immune status. Effective screening, early vaccination, and new diagnostic tools are essential for reducing the burden of HR-HPV-related diseases, especially in high-risk and immunocompromised populations. Ongoing research into the mechanisms of HR-HPV oncogenesis and improved therapeutic strategies will be crucial for future prevention and management.
Sources and full results
Most relevant research papers on this topic